Seidenberg, Harper launch Westlake Village BioPartners venture fund
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind gets cash infusion from United Therapeutics
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Europeans OK expanded use of Amgen’s Blincyto
The European Commission approved an expanded use for Amgen’s leukemia therapy Blincyto in treating pediatric patients Aug. 29. Based on results from a study of 93 pediatric patients, the approval allows its use in patients a year old or older with a particular type of relapsed or refractory acute lymphoblastic leukemia. “Historically, children with relapsed Read More →
Study results modest for Sienna psoriasis treatment
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Santa Barbara med tech startups secure funding
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MindBody teams up with Strava to serve athletes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sienna Biopharmaceuticals losses higher than analysts expected
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
